The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
Open accessAbstract
We conducted a phase I-II study of the safety, tolerance, and plasma pharmacokinetics of liposomal amphotericin B (L-AMB; AmBisome) in order to determine its maximally tolerated dosage (MTD) in patients with infections due to Aspergillus spp. and other filamentous fungi. Dosage cohorts consisted of 7.5, 10.0, 12.5, and 15.0 mg/kg of body weight/day; a total of 44 patients were enrolled, of which 21 had a proven or probable infection (13 aspergillosis, 5 zygomycosis, 3 fusariosis). The MTD of L-AMB was at least 15 mg/kg/day. Infusion-related reactions of fever occurred in 8 (19%) and chills and/or rigors occurred in 5 (12%) of 43 patients. Three patients developed a syndrome of substernal chest tightness, dyspnea, and flank pain, which was relieved by diphenhydramine. Serum creatinine increased two times above baseline in 32% of the patients, but this was not dose related. Hepatotoxicity developed in one patient. Steady-state plasma pharmacokinetics were achieved by day 7. The maximum concentration of drug in plasma (Cmax) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 μg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC 24) changed to 692, 1,062, 860, and 554 μg · h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively. These data indicate that L-AMB follows dose-related changes in disposition processing (e.g., clearance) at dosages of ≥7.5 mg/kg/day. Because several extremely ill patients had early death, success was determined for both the modified intent-to-treat and evaluable (7 days of therapy) populations. Response rates (defined as complete response and partial response) were similar for proven and probable infections. Response and stabilization, respectively, were achieved in 36 and 16% of the patients in the modified intent-to-treat population (n= 43) and in 52 and 13% of the patients in the 7-day evaluable population (n= 31). These findings indicate that L-AMB at dosages as high as 15 mg/kg/day follows nonlinear saturation-like kinetics, is well tolerated, and can provide effective therapy for aspergillosis and other filamentous fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationAmphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Wald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742 · cited 2×
“Cancer treatment and bone marrow transplantation/stem cell transplantation (BMT/SCT) regimens involve intensive cytotoxic chemotherapy, which often leads to prolonged myelosuppression and increased risk for opportunistic mycoses (5, 30, 31, 33, 39).”
BackgroundBoutati, E. I., & Anaissie, E. J. (1997) · Blood · doi:10.1182/blood.v90.3.999 · Cited by 587
Self-citationWingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Self-citationLipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Self-citationGroll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Self-citationOpportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and Review
Anaissie, E. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s43 · Cited by 364
Self-citationLeenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
Walsh, T. J., & Groll, A. H. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.010404.x · Cited by 294
Self-citationRingden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M. A., Gorin, N. C., Klastersky, J., Fenaux, P., et al. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.73 · Cited by 280
New Spectrum of Fungal Infections in Patients with Cancer
Anaissie, E., Bodey, G. P., Kantarjian, H., Ro, J., Vartivarian, S. E., Hopfer, R., Hoy, J., & Rolston, K. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.369 · Cited by 259
Self-citationDenning, D. W., Marinus, A., Cohen, J., Spence, D., Herbrecht, R., Pagano, L., Kibbler, C., Kermery, V., Offner, F., Cordonnier, C., et al. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)80173-4 · Cited by 256
Adler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., & Adler-Moore, J. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.49 · Cited by 203
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
Mehta, R., Lopez-Berestein, G., Hopfer, R., Mills, K., & Juliano, R. L. (1984) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(84)90135-4 · Cited by 192
Walsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, N. I., Whitcomb, P. O., Jarosinski, P., Boswell, G., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189
Self-citationFrancis, P., Lee, J. W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J., Pizzo, P. A., & Walsh, T. J. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.2.356 · Cited by 185
Self-citationMills, W., Chopra, R., Linch, D. C., & Goldstone, A. H. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04825.x · Cited by 171
Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 171
Walsh, T. J., Hiemenz, J. W., & Anaissie, E. J. (1996) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70303-2 · Cited by 136
Self-citationFleming, R. V., Kantarjian, H. M., Husni, R., Rolston, K. V. I., Lim, J. T., RAAD, I. I., Pierce, S. A., Cortes, J. E., & Estey, E. H. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097650 · Cited by 134
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134
Self-citationNg, T., & Denning, D. W. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100129015 · Cited by 134
Advances in blood substitute research
McLeod, A. J. (1984) · FEBS Letters · doi:10.1016/0014-5793(84)80894-7 · Cited by 134
Pannuti, C. M., Gingrich, R., Pfaller, M. A., kao, C., & Wenzel, R. P. (1992) · Cancer · doi:10.1002/1097-0142(19920601)69:11<2653::aid-cncr2820691106>3.0.co;2-8 · Cited by 116
Pittet, D. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.11.1177 · Cited by 115
Arning, M., Kliche, K. O., Heer‐Sonderhoff, A. H., & Wehmeier, A. (1995) · Mycoses · doi:10.1111/j.1439-0507.1995.tb00020.x · Cited by 110
AmBisome targeting to fungal infections.
Adler‐Moore, J. (1994) · PubMed · Cited by 107
Gondal, J. A., Swartz, R. P., & Rahman, A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1544 · Cited by 101
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
Perkins, W. R., Minchey, S. R., Boni, L. T., Swenson, C. E., Popescu, M. C., Pasternack, R. F., & Janoff, A. S. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90414-h · Cited by 87
van Etten, E. W. M., Otte-Lambillion, M., van Vianen, W., ten Kate, M. T., & Bakker‐Woudenberg, I. A. J. M. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.4.509 · Cited by 86
Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
Levine, S. J., Walsh, T. J., Martinez, A. D., Eichacker, P. Q., Lopez‐Berestein, G., & Natanson, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-664 · Cited by 84
Self-citationInfluence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B
Wasan, K. M., Rosenblum, M. G., Cheung, L. H., & Lopez‐Berestein, G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.223 · Cited by 84
Wasan, K. M., Morton, R. E., Rosenblum, M. G., & Lopez‐Berestein, G. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830716 · Cited by 82
Allende, M. C., Lee, J. W., Francis, P., Garrett, K. F., Dollenberg, H., Berenguer, J., Lyman, C. A., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.518 · Cited by 70
Self-citationWasan, K. M., Kennedy, A. L., Cassidy, S. M., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3146 · Cited by 64
Walsh, T. J., Garrett, K. F., Feurerstein, E., GIRTON, M. E., Allende, M. C., Bacher, J. D., Francesconi, A., Schaufele, R. L., & Pizzo, P. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.5.1065 · Cited by 58
Self-citationJohnson, M. D., Drew, R. H., & Perfect, J. R. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03934.x · Cited by 53
Louie, A., Baltch, A. L., Franke, M. A., Smith, R. P., & Gordon, M. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.6.975 · Cited by 48
Wasan, K. M., Grossie, V. B., & Lopez‐Berestein, G. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2224 · Cited by 41
Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.
Heinemann, V., Kähny, B., Debus, A., Wachholz, K., & Jehn, U. (1994) · PubMed · Cited by 38
van Etten, E. W. M., Snijders, S. V., van Vianen, W., & Bakker‐Woudenberg, I. A. J. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2431 · Cited by 24
Dose-Dependent Pharmacokinetics of Amphotericin B Lipid Complex in Rabbits
Walsh, T. J., Jackson, A. J., Lee, J. W., Amantea, M., Sein, T., Bacher, J. D., & Zech, L. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2068-2076.2000 · Cited by 23
Self-citationEmerging Fungal Pathogens: Evolving Challenges to Immunocompromised Patients
Walsh, T. J. (2014) · ASM Press eBooks · doi:10.1128/9781555816940.ch15 · Cited by 7
Self-citation
Cited by
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationCornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationDevelopment of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 886
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 751
Metadata
- Authors
- Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2001-12
- Volume
- 45
- Issue
- 12
- Pages
- 3487-3496
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2104240895
- Cited by
- 401
- References
- 48
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.